Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference
August 29 2018 - 4:05PM
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that
it will present at Baird's 2018 Global Healthcare Conference on
Wednesday, September 5 at 10:15 a.m. EDT at the InterContinental
New York Barclay in New York.
To access the live webcast of Paratek's presentation, please
visit http://wsw.com/webcast/baird52/prtk/. Please connect to the
web site at least 15 minutes prior to the live presentation to
ensure adequate time for any software downloads that may be
necessary to listen to the webcast. A replay of the webcast can be
accessed for up to 90 days following the live presentation.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of innovative
therapies based upon its expertise in novel tetracycline chemistry.
The company’s lead product candidate, Omadacycline, is a novel
investigational antibiotic with both once-daily intravenous (IV)
and oral formulations for the treatment of community-acquired
bacterial pneumonia (CABP), acute bacterial skin and skin structure
infections (ABSSSI), and urinary tract infections (UTI). A
modernized tetracycline, omadacycline is specifically designed to
overcome tetracycline resistance and exhibits activity across a
broad spectrum of bacteria, including Gram-positive, Gram-negative,
anaerobes, atypical bacteria, and other drug-resistant strains.
Omadacycline has been granted Qualified Infectious Disease
Product designation and Fast Track status by the U.S. Food and Drug
Administration (FDA) for the target indications of CABP, ABSSSI,
and UTI. The FDA has accepted the New Drug Applications for CABP
and ABSSSI and has granted omadacycline priority review. The
PDUFA date for both new drug applications is in
early October 2018. Paratek is also preparing a marketing
authorization application in the European Union. Paratek has
entered into a collaboration agreement with Zai Lab for the
development and commercialization of omadacycline in the greater
China region and retains all remaining global rights.
Under a research agreement with the U.S. Department of Defense,
omadacycline also is being studied against pathogenic agents
causing infectious diseases of public health and biodefense
importance, including plague and anthrax.
Paratek’s second Phase 3 product candidate, SEYSARA™
(sarecycline), is being developed by Allergan in the U.S. as a new
once-daily oral therapy for the treatment of acne. Allergan has
completed Phase 3 development activities for SEYSARA and its new
drug application was accepted for review by the U.S. FDA in
December 2017. The PDUFA date for SEYSARA is in the second half of
2018. Paratek retains all ex-U.S. rights to sarecycline.
Recognizing the serious threat of bacterial infections, Paratek
is dedicated to providing solutions that enable positive outcomes
and lead to better patient stories.
For more information, visit www.ParatekPharma.com or follow
@ParatekPharma on Twitter.
Forward Looking Statements
This press release contains forward-looking statements including
statements related to our overall strategy, product candidates,
prospects, potential and expected results, including statements
about the development, launch and commercialization of
omadacycline, the potential for omadacycline to treat ABSSSI, CABP,
UTI and other serious community-acquired bacterial infections, the
prospect of omadacycline providing broad-spectrum activity, our
ability to obtain regulatory approval of omadacycline and our
anticipated transition to a commercial stage organization. All
statements, other than statements of historical facts, included in
this press release are forward-looking statements, and are
identified by words such as “potential,” “prospective,” “prepare”
and other words and terms of similar meaning. These forward-looking
statements are based upon our current expectations and involve
substantial risks and uncertainties. We may not actually achieve
the plans, carry out the intentions or meet the expectations or
projections disclosed in our forward-looking statements and you
should not place undue reliance on these forward-looking
statements. Our actual results and the timing of events could
differ materially from those included in such forward-looking
statements as a result of these risks and uncertainties. These and
other risk factors are discussed under "Risk Factors" and elsewhere
in our Annual Report on Form 10-K for the year ended December 31,
2017, and our other filings with the Securities and Exchange
Commission. We expressly disclaim any obligation or undertaking to
update or revise any forward-looking statements contained
herein.
CONTACT:
Investor and Media Relations:Ben
Strain617-807-6688ir@ParatekPharma.com
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024